Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines, ...

Pfizer has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock ...

Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...

Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...

Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus on the stock. Pfizer's performance has been mixed lately. Shares dipped ...

JNJ’s stock has risen by almost 45%, whereas PFE has declined by 6%, greatly exceeding the S&P 500's 13% increase.

Pfizer (NYSE: PFE) has a market cap of $135 billion. They are both pharmaceutical industry giants with long and successful histori ...

Pfizer will buy Metsera for at least $47.50 per share. Pfizer could end up paying closer to $70 per share. Pfizer wants to sell GLP-1 weight loss drugs, and Metsera has four such candidates.

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...

Pfizer will reduce prices on drugs sold to Medicare patients. The Trump administration has made cutting prescription drug prices a priority. Ultimately, the administration aims to have Americans ...

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Why would Pfizer cut drug prices? President Donald Trump signed ...